Ligandal

Executive Summary

Ligandal is a San Francisco-based biotechnology company that leverages an AI-powered platform to design targeting peptides for precision drug delivery. By engineering these peptides to guide lipid nanoparticles and other delivery vehicles to specific molecular targets, Ligandal aims to enhance the efficacy and safety of RNA, gene, and advanced therapies. Founded in 2014, the company has built a substantial intellectual property portfolio with over 80 global patents. While still private and pre-revenue, its technology addresses a critical bottleneck in the delivery of next-generation therapeutics, potentially enabling wider therapeutic windows and reduced off-target effects. The platform's versatility across multiple therapeutic modalities positions Ligandal as a potential enabler or partner for biopharma companies developing genetic medicines. However, the company faces competition from other delivery technology firms and must demonstrate in vivo validation and scalable manufacturing to attract partnerships or advance its own pipeline.

Upcoming Catalysts (preview)

• Q3 2026Partnership with major pharma for delivery platform licensing40% success
• Q2 2026Publication of preclinical in vivo data for lead targeting peptide70% success
• Q4 2026Series B or later-stage funding round closure50% success